Results_of_Medical_Research_Council_phase_II_study_of_low_dose_cisplatin_and_methotrexate_in_the_primary_treatment_of_locally_advanced_(T3_and_T4)_transitional_cell_carcinoma_of_the_bladder._A_series_of_49_previously_untreated_patients_with_category_T3_or_T4_bladder_cancer_underwent_treatment_with_low_dose_methotrexate_and_cisplatin;_44_patients_were_eligible_for_assessment_of_response._Complete_response_(CR)_was_seen_in_5_patients_(11%)_and_partial_response_in_15_(34%)_(overall_response_rate_45%)._Treatment_was_reasonably_well_tolerated_with_no_major_morbidity_and_no_treatment-related_deaths._After_a_median_follow-up_of_3.5_years,_the_1-year_and_2-year_survival_rates_were_70_and_30%_respectively._Ten_patients_remain_recurrence-free_without_having_received_"definitive_local_therapy"_(cystectomy_and/or_radiotherapy)_at_follow-up_extending_from_20_to_50_months.